These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11813475)

  • 41. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
    Farkas K; Kolossváry E; Járai Z
    Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Falconer TM; Eikelboom JW; Hankey GJ; Norman PE
    Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
    Donnelly R
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cilostazol.
    Sorkin EM; Markham A
    Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapy of intermittent claudication.
    Doggrell SA
    Expert Opin Pharmacother; 2001 Nov; 2(11):1725-36. PubMed ID: 11825312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of cilostazol in the management of intermittent claudication.
    Chi YW; Lavie CJ; Milani RV; White CJ
    Vasc Health Risk Manag; 2008; 4(6):1197-203. PubMed ID: 19337533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
    Ikeda Y
    Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
    Liu Y; Fong M; Cone J; Wang S; Yoshitake M; Kambayashi J
    J Cardiovasc Pharmacol; 2000 Sep; 36(3):351-60. PubMed ID: 10975593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent claudication revisited: the value of medical therapy.
    Hiatt WR
    Arch Intern Med; 1999 Sep; 159(16):1955-6. PubMed ID: 10493329
    [No Abstract]   [Full Text] [Related]  

  • 58. Intermittent claudication: effective medical management of a common circulatory problem.
    Beebe HG
    Am J Cardiol; 2001 Jun; 87(12A):14D-18D. PubMed ID: 11434895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new treatment for peripheral arterial disease.
    Harv Heart Lett; 2001 Apr; 11(8):1-3. PubMed ID: 11340018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.